Levofloxacin hydrate
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Category | Antibiotics |
Catalog number | BBF-04635 |
CAS | 138199-71-0 |
Molecular Weight | 370.38 |
Molecular Formula | C18H21FN3O4.5 |
Purity | 98% |
Online Inquiry
Capabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
The hydrate form of Levofloxacin, an Ofloxacin derivative, could be commonly used as an antibacterial agent through influencing DNA replication. It is an antibiotic with activity against gram-negative bacteria.
- Specification
- Properties
- Reference Reading
- Price Product List
- QC Data
Related CAS | 100986-85-4 (free base) |
Synonyms | Levofloxacin Hemihydrate;138199-71-0;Levofloxacin hydrate;Nofaxin;Volequin;Levofloxacin (hydrate);Dynaquin;Ofloxacin, (s)-;6GNT3Y5LMF;Levofloxacin (as hemihydrate);UNII-6GNT3Y5LMF;RWJ-25213;(S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate(2:1);Levaquin (TN);(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, hemihydrate;7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-hydrate (2:1), (S)-;7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (3S)-;Levofloxacin [USAN];LEVOFLOXACIN [MART.];LEVOFLOXACIN [USP-RS];DTXSID60160533;RWJ 25213;(S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hemihydrate;Ofloxacin s-(-)-form hemihydrate;LEVOFLOXACIN [USP MONOGRAPH];LEVOFLOXACIN HEMIHYDRATE [EP MONOGRAPH];MFCD07772024;7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (3S)-; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (S)-; Dynaquin; Leeflox; Levofloxacin; Levofloxacin hydrate;Levofloxacin (USP);Quixin (TN);Iquix (TN);LevofloxacinHemihydrate;LEVOFLOXACIN [VANDF];(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1);Levofloxacin hydrate (JP18);LEVOFLOXACIN HEMIHIDRATED;SCHEMBL1650602;CHEMBL5315124;LEVOFLOXACIN [ORANGE BOOK];LEVOFLOXACIN HYDRATE [JAN];AKOS015896149;KS-1077;Levofloxacin [USAN:USP:INN:BAN:JAN];LEVOFLOXACIN HEMIHYDRATE [WHO-DD];7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrate (2:1), (S)-;DA-54880;D00588;OFLOXACIN S-(-)-FORM HEMIHYDRATE [MI];A886273;EN300-20644132;Q47495791;Levofloxacin, United States Pharmacopeia (USP) Reference Standard;Levofloxacin Hemihydrate, Pharmaceutical Secondary Standard; Certified Reference Material;(S)-(-)-Ofloxacine; Levofloxacine; (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hydrochloride; Levofloxacin hemihydrate;(S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid Hemihydrate;(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hemihydrate;bis((2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid) hydrate; |
Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
IUPAC Name | (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;hydrate |
Canonical SMILES | O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.[0.5H2O] |
InChI | InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1 |
InChI Key | SUIQUYDRLGGZOL-RCWTXCDDSA-N |
Source | Synthetic |
Appearance | Solid |
Application | Anti-Bacterial Agents |
Antibiotic Activity Spectrum | Gram-negative bacteria |
Boiling Point | 571.5°C at 760 mmHg |
Melting Point | 218-227°C |
Density | 1.48 g/cm3 |
Solubility | Slightly soluble in Basic Aqueous Solution, DMSO, Methanol |
BBF-05808 | Triptolide | Inquiry |
BBF-03774 | Cephalosporin C Zinc Salt | Inquiry |
BBF-05886 | Notoginsenoside R1 | Inquiry |
BBF-01851 | Fumagillin | Inquiry |
BBF-04621 | Artemisinin | Inquiry |
BBF-04609 | 1,1-Dimethylbiguanide hydrochloride | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
